AVE 1625

Key Product Details

Product Description

AVE 1625 is a potent and selective CB₁ receptor antagonist (IC₅₀ values are 25 and 10 nM for human and rat CB₁R, respectively). Exhibits >400-fold selectivity for CB₁ over CB₂ receptors. Attenuates Olanzapine (Cat. No. 4349) induced weight gain and food intake in rats with no effect on energy expenditure or motility. Also improves cognitive function in rodent schizophrenia models and ameliorates extrapyramidal side-effects of antipsychotics.

Product Specifications for AVE 1625

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AVE 1625

The following data is based on the product molecular weight 497.38.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.01 mL	10.05 mL	20.11 mL
5 mM	0.40 mL	2.01 mL	4.02 mL
10 mM	0.20 mL	1.01 mL	2.01 mL
50 mM	0.04 mL	0.20 mL	0.40 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Liebig Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB₁-antagonist AVE1625. Obesity 2010 PMID: 20168311
• Black AVE1625, a cannabinoid CB₁ receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl.) 2011 PMID: 21181124
• Herling CB₁ receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am.J.Physiol.Endocrinol.Metab. 2007 PMID: 17595216

Product Documents for AVE 1625